A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study)
Open Access
- 13 November 2017
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 6 (12) , 2909-2917
Abstract
S‐1 and irinotecan combination is attractive for breast cancer refractory to anthracyclines and taxanes. Patients with advanced human epidermal growth factor receptor 2 (HER2)‐negative breast cancer previously treated with anthracyclines and taxanes were eligible. Patients with brain metastases and homozygous for UGT1A1 *6 or *28 or compound heterozygous (*6/*28) were excluded. A dose‐escalation design was chosen for the phase I portion (level 1: irinotecan 80 mg/m2 days 1–8 and S‐1 80 mg/m2 days 1–14 every 3 weeks; level 2: irinotecan 100 mg/m2 and S‐1 80 mg/m2). Study objectives included determination of the recommended dose for phase II, response rate, progression‐free survival (PFS), and safety. Pharmacokinetics and CD34+ circulating endothelial cells (CECs) as pharmacodynamics were also analyzed. Thirty‐seven patients were included. One patient at each level developed dose‐limiting toxicities; therefore, level 2 was the recommended dose for phase II. Diarrhea was more common in patients possessing a *6 or *28 allele compared with wild‐type homozygous patients (46% and 25%). Among 29 patients treated at level 2, PFS was longer for UGT1A1 wt/*6 and wt/*28 patients than for wt/wt patients (12 vs. 8 months, P = 0.06). PFS was significantly longer in patients with a larger‐than‐median SN‐38 area under the curve (AUC) than in those with a smaller AUC (P = 0.039). There was an association between clinical benefit and reduction in baseline CD34+ CECs by S‐1 (P = 0.047). The combination of irinotecan and S‐1 is effective and warrants further investigation.Keywords
Funding Information
- Grant-in-Aid for Scientific Research (JP24590656)
- Advanced Clinical Research Organization
This publication has 19 references indexed in Scilit:
- Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activityBlood, 2005
- Randomized Phase II Study of Two Irinotecan Schedules for Patients With Metastatic Breast Cancer Refractory to an Anthracycline, a Taxane, or BothJournal of Clinical Oncology, 2004
- Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of IrinotecanJournal of Clinical Oncology, 2004
- A phase II study of S-1 in patients with metastatic breast cancer — A Japanese trial by the S-1 cooperative study group, breast cancer working groupBreast Cancer, 2004
- Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumorsInternational Journal of Molecular Medicine, 2003
- Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.2003
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002
- Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.2000
- Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000